Key Insights

Highlights

Success Rate

91% trial completion (above average)

Published Results

14 trials with published results (9%)

Research Maturity

79 completed trials (49% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

4.9%

8 terminated out of 162 trials

Success Rate

90.8%

+4.3% vs benchmark

Late-Stage Pipeline

10%

17 trials in Phase 3/4

Results Transparency

18%

14 of 79 completed with results

Key Signals

14 with results91% success

Data Visualizations

Phase Distribution

102Total
Not Applicable (35)
Early P 1 (6)
P 1 (19)
P 2 (25)
P 3 (7)
P 4 (10)

Trial Status

Completed79
Recruiting30
Unknown20
Active Not Recruiting10
Not Yet Recruiting9
Terminated8

Trial Success Rate

90.8%

Benchmark: 86.5%

Based on 79 completed trials

Clinical Trials (162)

Showing 20 of 20 trials
NCT05644795Not ApplicableCompletedPrimary

Wheat-free Diet in the Treatment of Sjogren's Syndrome

NCT05879419Phase 4Active Not Recruiting

Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases

NCT03711214Not ApplicableActive Not RecruitingPrimary

Immune Profile of Saliva and Serum of Patients With Primary Sjögren´s Syndrome

NCT06437652CompletedPrimary

An AI Algorithm for Lymphocyte Focus Score of Minor Salivary Gland Biopsy Samples for Diagnosing Sjogren's Syndrome

NCT05985915Phase 3Active Not RecruitingPrimary

A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.

NCT02327884Recruiting

Characterization of Diseases With Salivary Gland Involvement

NCT01425892RecruitingPrimary

The Pathogenesis and Natural History of Sjogren's Disease

NCT06741969Phase 3Active Not RecruitingPrimary

Nipocalimab in Moderate to Severe Sjogren's Disease

NCT03157011Not ApplicableCompletedPrimary

Evaluation of the Prevalence of Functional Digestive Disorders During Primary Sjögren Gougerot Syndrome

NCT07281456Phase 2RecruitingPrimary

Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren Disease

NCT02370225Not ApplicableCompletedPrimary

Aerobic Exercise in Primary Sjögren's Syndrome

NCT07041099Phase 1Recruiting

A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease

NCT05016297Phase 2CompletedPrimary

Efficacy and Safety of Baricitinib in Sjogren's Syndrome

NCT06548607Early Phase 1Recruiting

Clinical Study on Targeted CD19 or CD19-BCMA CAR-T Therapy for Autoimmune Diseases

NCT07236762Phase 1Recruiting

An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases

NCT05056012Not Yet Recruiting

Penn SICCA Follow-up Study

NCT04402086Recruiting

Rheumatology Patient Registry and Biorepository

NCT06549296Early Phase 1Suspended

Clinical Study on Targeted CD19CAR-T Therapy for Autoimmune Diseases

NCT06104124Phase 3Active Not RecruitingPrimary

A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity

NCT03276923Recruiting

Maternal Autoimmune Disease Research Alliance (MADRA) Registry

Scroll to load more

Research Network

Activity Timeline